• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

标准剂量和分剂量17DD黄热病疫苗诱导的免疫反应。

Immune response induced by standard and fractional doses of 17DD yellow fever vaccine.

作者信息

Abdala-Torres Thais, Campi-Azevedo Ana Carolina, da Silva-Pereira Rosiane Aparecida, Dos Santos Luara Isabela, Henriques Priscilla Miranda, Costa-Rocha Ismael Artur, Otta Dayane Andriotti, Peruhype-Magalhães Vanessa, Teixeira-Carvalho Andréa, Araújo Márcio Sobreira Silva, Fernandes Eder Gatti, Sato Helena Keico, Fantinato Francieli Fontana Sutile Tardetti, Domingues Carla Magda Allan Santos, Kallás Esper Georges, Tomiyama Helena Tomoko Iwashita, Lemos Jandira Aparecida Campos, Coelho-Dos-Reis Jordana Grazziela, de Lima Sheila Maria Barbosa, Schwarcz Waleska Dias, de Souza Azevedo Adriana, Trindade Gisela Freitas, Ano Bom Ana Paula Dinis, da Silva Andrea Marques Vieira, Fernandes Camilla Bayma, Camacho Luiz Antônio Bastos, de Sousa Maia Maria de Lourdes, Martins-Filho Olindo Assis, do Antonelli Lis Ribeiro do Valle

机构信息

Laboratório de Biologia e Imunologia de Doenças Infecciosas e Parasitárias, Instituto René Rachou, FIOCRUZ-Minas, Belo Horizonte, MG, Brazil.

Departamento de Bioquímica e Imunologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil.

出版信息

NPJ Vaccines. 2024 Mar 8;9(1):54. doi: 10.1038/s41541-024-00836-w.

DOI:10.1038/s41541-024-00836-w
PMID:38459059
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10923915/
Abstract

The re-emergence of yellow fever (YF) urged new mass vaccination campaigns and, in 2017, the World Health Organization approved the use of the fractional dose (FD) of the YF vaccine due to stock shortage. In an observational cross-sectional investigation, we have assessed viremia, antibodies, soluble mediators and effector and memory T and B-cells induced by primary vaccination of volunteers with FD and standard dose (SD). Similar viremia and levels of antibodies and soluble markers were induced early after immunization. However, a faster decrease in the latter was observed after SD. The FD led to a sustained expansion of helper T-cells and an increased expression of activation markers on T-cells early after vaccination. Although with different kinetics, expansion of plasma cells was induced upon SD and FD immunization. Integrative analysis reveals that FD induces a more complex network involving follicular helper T cells and B-cells than SD. Our findings substantiate that FD can replace SD inducing robust correlates of protective immune response against YF.

摘要

黄热病(YF)的再度出现促使开展新的大规模疫苗接种运动,2017年,由于库存短缺,世界卫生组织批准使用黄热病疫苗的分剂量(FD)。在一项观察性横断面调查中,我们评估了用FD和标准剂量(SD)对志愿者进行初次疫苗接种后诱导产生的病毒血症、抗体、可溶性介质以及效应和记忆T细胞及B细胞。免疫接种后早期诱导产生了相似的病毒血症以及抗体和可溶性标志物水平。然而,在接种SD后观察到后者下降得更快。FD导致辅助性T细胞持续扩增,且在接种疫苗后早期T细胞上激活标志物的表达增加。尽管动力学不同,但SD和FD免疫接种均诱导了浆细胞的扩增。综合分析表明,与SD相比,FD诱导了一个涉及滤泡辅助性T细胞和B细胞的更复杂网络。我们的研究结果证实,FD可替代SD诱导针对黄热病的强大保护性免疫反应相关指标。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b8e5/10923915/c4ac1d73ad9d/41541_2024_836_Fig9_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b8e5/10923915/3005cb5dd815/41541_2024_836_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b8e5/10923915/a6ec1d8dd595/41541_2024_836_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b8e5/10923915/2fb13365e1be/41541_2024_836_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b8e5/10923915/07f5bb62dca8/41541_2024_836_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b8e5/10923915/459fb8b28491/41541_2024_836_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b8e5/10923915/3e2f7e645d6c/41541_2024_836_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b8e5/10923915/f97666ec8bba/41541_2024_836_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b8e5/10923915/d66055e4f0f5/41541_2024_836_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b8e5/10923915/c4ac1d73ad9d/41541_2024_836_Fig9_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b8e5/10923915/3005cb5dd815/41541_2024_836_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b8e5/10923915/a6ec1d8dd595/41541_2024_836_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b8e5/10923915/2fb13365e1be/41541_2024_836_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b8e5/10923915/07f5bb62dca8/41541_2024_836_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b8e5/10923915/459fb8b28491/41541_2024_836_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b8e5/10923915/3e2f7e645d6c/41541_2024_836_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b8e5/10923915/f97666ec8bba/41541_2024_836_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b8e5/10923915/d66055e4f0f5/41541_2024_836_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b8e5/10923915/c4ac1d73ad9d/41541_2024_836_Fig9_HTML.jpg

相似文献

1
Immune response induced by standard and fractional doses of 17DD yellow fever vaccine.标准剂量和分剂量17DD黄热病疫苗诱导的免疫反应。
NPJ Vaccines. 2024 Mar 8;9(1):54. doi: 10.1038/s41541-024-00836-w.
2
Previous biological therapy and impairment of the IFN-γ/IL-10 axis are associated with low immune response to 17DD-YF vaccination in patients with spondyloarthritis.先前的生物治疗和 IFN-γ/IL-10 轴的损伤与脊柱关节炎患者对 17DD-YF 疫苗接种的低免疫反应相关。
Vaccine. 2022 Jul 30;40(32):4580-4593. doi: 10.1016/j.vaccine.2022.05.071. Epub 2022 Jun 18.
3
Short-Lived Immunity After 17DD Yellow Fever Single Dose Indicates That Booster Vaccination May Be Required to Guarantee Protective Immunity in Children.单次接种 17DD 黄热病减毒活疫苗后短暂的免疫持久性表明,为保证儿童的保护性免疫,可能需要加强免疫接种。
Front Immunol. 2019 Sep 26;10:2192. doi: 10.3389/fimmu.2019.02192. eCollection 2019.
4
Booster dose after 10 years is recommended following 17DD-YF primary vaccination.17DD-YF 初次接种疫苗后,建议 10 年后进行加强剂量接种。
Hum Vaccin Immunother. 2016;12(2):491-502. doi: 10.1080/21645515.2015.1082693.
5
Comprehensive landscape of neutralizing antibody and cell-mediated response elicited by the 1/5 fractional dose of 17DD-YF primary vaccination in adults.成人接种 17DD-YF 初免 1/5 剂次后诱导的中和抗体和细胞介导免疫应答全景图。
Sci Rep. 2024 Apr 2;14(1):7709. doi: 10.1038/s41598-024-57645-3.
6
Impact of synthetic and biological immunomodulatory therapy on the duration of 17DD yellow fever vaccine-induced immunity in rheumatoid arthritis.合成和生物免疫调节疗法对类风湿关节炎患者 17DD 黄热病疫苗诱导免疫持续时间的影响。
Arthritis Res Ther. 2019 Mar 14;21(1):75. doi: 10.1186/s13075-019-1854-6.
7
Subdoses of 17DD yellow fever vaccine elicit equivalent virological/immunological kinetics timeline.17DD 黄热病疫苗的亚剂量引发等效的病毒学/免疫学动力学时间线。
BMC Infect Dis. 2014 Jul 15;14:391. doi: 10.1186/1471-2334-14-391.
8
Exploratory study of humoral and cellular immunity to 17DD Yellow Fever vaccination in children and adults residents of areas without circulation of Yellow Fever Virus.17DD 黄热病疫苗接种后儿童和成人的体液和细胞免疫的探索性研究。居住在无黄热病病毒传播地区的人群。
Vaccine. 2022 Jan 31;40(5):798-810. doi: 10.1016/j.vaccine.2021.12.029. Epub 2021 Dec 27.
9
17DD Yellow Fever Revaccination and Heightened Long-Term Immunity in Populations of Disease-Endemic Areas, Brazil.17DD 黄热病加强免疫和长期免疫在巴西疾病流行地区的人群中。
Emerg Infect Dis. 2019 Aug;25(8):1511-1521. doi: 10.3201/eid2508.181432. Epub 2019 Aug 17.
10
17DD and 17D-213/77 yellow fever substrains trigger a balanced cytokine profile in primary vaccinated children.17DD 和 17D-213/77 黄热病减毒株在初次接种儿童中引发平衡的细胞因子谱。
PLoS One. 2012;7(12):e49828. doi: 10.1371/journal.pone.0049828. Epub 2012 Dec 10.

引用本文的文献

1
Challenges in Emerging and Reemerging Arboviral Diseases: The Examples of Oropouche and Yellow Fever.新发和再发虫媒病毒病面临的挑战:奥罗普切病毒病和黄热病实例
Pathogens. 2025 Jun 23;14(7):621. doi: 10.3390/pathogens14070621.
2
Profile of the B cell receptor repertoire and antibody responses upon 17DD-YF vaccine boosting.17DD-YF疫苗加强免疫后的B细胞受体库及抗体反应概况
bioRxiv. 2025 Jul 1:2025.06.24.660700. doi: 10.1101/2025.06.24.660700.
3
The Yellow Fever Outbreak in Brazil (2016-2018): How a Low Vaccination Coverage Can Contribute to Emerging Disease Outbreaks.

本文引用的文献

1
Immunogenicity and safety of fractional doses of 17D-213 yellow fever vaccine in HIV-infected people in Kenya (YEFE): a randomised, double-blind, non-inferiority substudy of a phase 4 trial.肯尼亚感染 HIV 人群中 17D-213 黄热病疫苗分剂量的免疫原性和安全性(YEFE):一项 4 期试验的随机、双盲、非劣效性亚研究。
Lancet Infect Dis. 2023 Aug;23(8):974-982. doi: 10.1016/S1473-3099(23)00114-7. Epub 2023 Apr 28.
2
Factors associated with yellow fever vaccine failure: A systematic literature review.与黄热病疫苗失效相关的因素:一项系统文献综述。
Vaccine. 2023 Mar 24;41(13):2155-2169. doi: 10.1016/j.vaccine.2023.02.007. Epub 2023 Feb 24.
3
巴西黄热病疫情(2016 - 2018年):低疫苗接种覆盖率如何导致新发病原体引发的疫情爆发。
Microorganisms. 2025 May 31;13(6):1287. doi: 10.3390/microorganisms13061287.
Exploratory study of humoral and cellular immunity to 17DD Yellow Fever vaccination in children and adults residents of areas without circulation of Yellow Fever Virus.
17DD 黄热病疫苗接种后儿童和成人的体液和细胞免疫的探索性研究。居住在无黄热病病毒传播地区的人群。
Vaccine. 2022 Jan 31;40(5):798-810. doi: 10.1016/j.vaccine.2021.12.029. Epub 2021 Dec 27.
4
CCL3, CCL5, IL-15, IL-1Ra and VEGF compose a reliable algorithm to discriminate classes of adverse events following 17DD-YF primary vaccination according to cause-specific definitions.CCL3、CCL5、IL-15、IL-1Ra 和 VEGF 构成了一个可靠的算法,可以根据特定病因的定义来区分 17DD-YF 初免后不良事件的类别。
Vaccine. 2021 Jul 13;39(31):4359-4372. doi: 10.1016/j.vaccine.2021.05.101. Epub 2021 Jun 16.
5
Serum biomarker profile orchestrating the seroconversion status of patients with autoimmune diseases upon planned primary 17DD Yellow fever vaccination.计划原发性 17DD 黄热病疫苗接种后,血清生物标志物谱协调自身免疫性疾病患者的血清转化状态。
Sci Rep. 2021 May 17;11(1):10431. doi: 10.1038/s41598-021-89770-8.
6
B cell memory: building two walls of protection against pathogens.B 细胞记忆:构建抵御病原体的双重保护墙。
Nat Rev Immunol. 2020 Apr;20(4):229-238. doi: 10.1038/s41577-019-0244-2. Epub 2019 Dec 13.
7
Short-Lived Immunity After 17DD Yellow Fever Single Dose Indicates That Booster Vaccination May Be Required to Guarantee Protective Immunity in Children.单次接种 17DD 黄热病减毒活疫苗后短暂的免疫持久性表明,为保证儿童的保护性免疫,可能需要加强免疫接种。
Front Immunol. 2019 Sep 26;10:2192. doi: 10.3389/fimmu.2019.02192. eCollection 2019.
8
17DD Yellow Fever Revaccination and Heightened Long-Term Immunity in Populations of Disease-Endemic Areas, Brazil.17DD 黄热病加强免疫和长期免疫在巴西疾病流行地区的人群中。
Emerg Infect Dis. 2019 Aug;25(8):1511-1521. doi: 10.3201/eid2508.181432. Epub 2019 Aug 17.
9
Duration of Humoral and Cellular Immunity 8 Years After Administration of Reduced Doses of the 17DD-Yellow Fever Vaccine.接种减毒 17DD 黄热病疫苗 8 年后的体液和细胞免疫持续时间。
Front Immunol. 2019 Jun 21;10:1211. doi: 10.3389/fimmu.2019.01211. eCollection 2019.
10
Yellow Fever Virus: Knowledge Gaps Impeding the Fight Against an Old Foe.黄热病病毒:阻碍抗击旧敌的知识空白。
Trends Microbiol. 2018 Nov;26(11):913-928. doi: 10.1016/j.tim.2018.05.012. Epub 2018 Jun 19.